NexturnBioscience (Korea) Top Management
089140 Stock | KRW 3,450 240.00 6.50% |
NexturnBioscience employs about 56 people. The company is managed by 5 executives with a total tenure of roughly 35 years, averaging almost 7.0 years of service per executive, having 11.2 employees per reported executive. Analysis of NexturnBioscience's management performance can provide insight into the company performance.
Yeong Jung CEO Chief Executive Officer, Director |
NexturnBioscience |
NexturnBioscience Management Team Effectiveness
The company has return on total asset (ROA) of 0.0793 % which means that it generated a profit of $0.0793 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 2.0662 %, meaning that it generated $2.0662 on every $100 dollars invested by stockholders. NexturnBioscience's management efficiency ratios could be used to measure how well NexturnBioscience manages its routine affairs as well as how well it operates its assets and liabilities.NexturnBioscience Workforce Comparison
NexturnBioscience Co is rated fourth in number of employees category among its peers. The total workforce of Machinery industry is presently estimated at about 497. NexturnBioscience retains roughly 56.0 in number of employees claiming about 11% of all equities under Machinery industry.
The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.14 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.14. NexturnBioscience Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. NexturnBioscience Price Series Summation is a cross summation of NexturnBioscience price series and its benchmark/peer.
NexturnBioscience Notable Stakeholders
A NexturnBioscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NexturnBioscience often face trade-offs trying to please all of them. NexturnBioscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NexturnBioscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Yeong Jung | Chief Executive Officer, Director | Profile | |
Dong Kim | Non-Executive Independent Director | Profile | |
Wung Moon | Director | Profile | |
Jae Lee | Internal Auditor | Profile | |
YoungHwa Jung | Chief Officer | Profile |
About NexturnBioscience Management Performance
The success or failure of an entity such as NexturnBioscience often depends on how effective the management is. NexturnBioscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NexturnBioscience management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NexturnBioscience management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
,Ltd. develops and produces CNC automatic lathe machines in Korea and internationally. ,Ltd. was founded in 2000 and is based in Yongin, South Korea. NEXTURNBIO is traded on Korean Securities Dealers Automated Quotations in South Korea.
Please note, the presentation of NexturnBioscience's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NexturnBioscience's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of NexturnBioscience's management manipulating its earnings.
NexturnBioscience Workforce Analysis
Traditionally, organizations such as NexturnBioscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NexturnBioscience within its industry.NexturnBioscience Manpower Efficiency
Return on NexturnBioscience Manpower
Revenue Per Employee | 303.1M | |
Revenue Per Executive | 3.4B | |
Net Loss Per Employee | 71.4M | |
Net Loss Per Executive | 799.4M | |
Working Capital Per Employee | 545.7M | |
Working Capital Per Executive | 6.1B |
Complementary Tools for NexturnBioscience Stock analysis
When running NexturnBioscience's price analysis, check to measure NexturnBioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NexturnBioscience is operating at the current time. Most of NexturnBioscience's value examination focuses on studying past and present price action to predict the probability of NexturnBioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NexturnBioscience's price. Additionally, you may evaluate how the addition of NexturnBioscience to your portfolios can decrease your overall portfolio volatility.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |